

PATRICK J. LEAHY, VERMONT, CHAIRMAN

HERB KOHL, WISCONSIN
DIANNE FEINSTEIN, CALIFORNIA
CHARLES E. SCHUMER, NEW YORK
RICHARD J. DURBIN, ILLINOIS
SHELDON WHITEHOUSE, RHODE ISLAND
AMY KLOBUCHAR, MINNESOTA
AL FRANKEN, MINNESOTA
CHRISTOPHER A. COONS, DELAWARE
RICHARD BLUMENTHAL, CONNECTICUT

CHARLES E. GRASSLEY, IOWA
ORRIN G. HATCH, UTAH
JON KYL, ARIZONA
JEFF SESSIONS, ALABAMA
LINDSEY O. GRAHAM, SOUTH CAROLINA
JOHN CORNYN, TEXAS
MICHAEL S. LEE, UTAH
TOM COBURN, OKLAHOMA

United States Senate

COMMITTEE ON THE JUDICIARY
WASHINGTON, DC 20510-6275

BRUCE A. COHEN, *Chief Counsel and Staff Director*
KOLAN L. DAVIS, *Republican Chief Counsel and Staff Director*

May 4, 2011

Via Electronic Transmission

Tod R. Ibrahim
Executive Director
The American Society of Nephrology
1725 I St. NW, Suite 510
Washington, DC, 20006

Dear Mr. Ibrahim:

In December 2009, I asked for an accounting of industry funding that The American Society of Nephrology (ASN) receives from pharmaceutical and medical device companies as well as foundations established by these companies or the insurance industry. I appreciate your response, which I have attached to this letter. I write today to follow up on any efforts by your organization to improve transparency and accountability in its relationships with the pharmaceutical and device industries.

As I stated in my previous letter, I started my inquiry, in part, as a result of accounts documenting the lack of transparency in financial relationships between the pharmaceutical industry and nonprofit health and medical organizations. Specifically, I cited the April 2008 article in *The Wall Street Journal*, which reported that industry representatives, including ten major drug companies, had formed a coalition to promote looser restrictions on off-label marketing.¹ The coalition had asked the National Alliance on Mental Illness (NAMI) to speak in favor of this issue.

In response to my concerns in my April 2009 letter to NAMI, NAMI began to voluntarily disclose to the public any amount of funding exceeding \$5,000 that it received from pharmaceutical companies and foundations on its website. Further, NAMI began to provide a brief description of the purpose of the funding on its website. I commend NAMI for its leadership and had hoped that when I reached out to your organization and 32 others, your organization would follow NAMI's example and begin posting similar funding information on ASN's website.

As of the date of this letter, it appears that no additional information regarding your organization's industry funding has been posted on the ASN's website. If ASN is currently

¹ Alicia Mundy, "Off-Label Use of Drugs Gets a Push --- Big Pharma Lobbies Washington to Relax Rules on Marketing," *The Wall Street Journal*, April 18, 2008.

taking steps to enhance the transparency of its financial relationships with the pharmaceutical and device industries, I would appreciate information regarding those steps. If not, please explain why your organization does not support the disclosure of funding it receives from pharmaceutical and device companies.

The Medicare Payment Advisory Commission (MedPAC) recommended in a report to Congress in March 2009 that Congress require that pharmaceutical and device companies report their financial relationships with physician groups, patient organizations, and others. More specifically MedPAC said the following:

Given the potential benefits of public reporting, we recommend that the Congress mandate the reporting of comprehensive information on industry relationships with physicians and other health care entities and that the Secretary post this information on a public searchable website.²

MedPAC then went on to say in Recommendation 5-1 that:

The Congress should require all manufacturers and distributors of drugs, biologicals, medical devices, and medical supplies (and their subsidiaries) to report to the Secretary their financial relationship with: . . . physician groups and other prescribers . . . patient organizations; and professional organizations.³

I look forward to working with you and other health and medical organizations to further increase sunshine on financial relationships.

Thank you for your cooperation and attention in this matter. I would appreciate a response by May 25, 2011. If you have any questions, please do not hesitate to contact Brian Downey for the Committee on the Judiciary at (202) 224-5225.

Sincerely,



Charles E. Grassley
Ranking Member

Attachments

² Medicare Payment Advisory Commission, "Public reporting of physicians' financial relationships," Report to Congress: Medicare Payment Policy, March 2009.

³ *Id.*

Attachment

December 21, 2009

The Honorable Charles E. Grassley
US Senate
135 Hart Senate Office Building
Washington, DC 20510-1501

Dear Senator Grassley:

On behalf of the American Society of Nephrology (ASN), thank you for the opportunity to describe ASN's relationship with "pharmaceutical, medical device companies, foundations established by these companies, or the insurance industry" that provided funding to ASN from January 1, 2006, to the present. ASN is pleased to respond to your request and interested in the possibility of meeting with you and your staff to discuss ways to protect the health of beneficiaries of the Medicare and Medicaid programs as well as safeguard taxpayer dollars Congress authorizes for these programs.

As stated on ASN's website, the Society "is committed to maintaining educational and scientific objectivity as well as institutional integrity through disclosure, evaluation, standardization, and transparency in interactions with industry." ASN has made a sincere effort to meet your two-week deadline for providing this information. Given this short timeline, ASN understands that you or your staff may ask the Society to provide additional information or to clarify aspects of its response.

ASN is a not-for-profit association serving more than 11,100 physicians, scientists, and other caregiver members dedicated to providing high-quality care to patients, conducting cutting-edge research, and educating the next generation of health professionals. To meet its mission, ASN offers educational content through meetings and other activities, disseminates peer-reviewed science through self-published journals, and offers research grants to young investigators and more senior scientists who are between funding. As the most significant organization of kidney care professionals in the world, ASN has led the fight against kidney disease—which afflicts approximately 30 million people in the United States alone—for nearly 50 years.

Since 2000, ASN has been accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. As a result of being an accredited CME provider, ASN has procedures in place to regulate funding from all commercial interests, defined by ACCME as "any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients." ASN, therefore, includes in this response a description of its financial relationships with all such commercial interests, not just the biotechnology, medical device, pharmaceutical, and insurance industries identified in your December 7, 2009, request.

For your review, **Tab 1** lists all of the revenue ASN has generated from commercial interests since January 1, 2006. This information is organized in four separate spreadsheets, one for each year. Each spreadsheet includes the names of the commercial interests, the amount of funding ASN received from these entities, and the reasons for the support.

ASN's fiscal year is January 1 to December 31. Audits by an independent certified public accounting firm (Renner and Company) are performed in January of the year following the fiscal year end. In January 2010, Renner and Company will audit ASN's finances for fiscal year 2009. As a result, the information summarized in **Tab 1** for 2006, 2007, and 2008 is based on audited data; the information for 2009 is subject to change pending final audited figures.

As illustrated in **Tab 1**, ASN generally receives funding from commercial interests related to one of four purposes:

1. **Exhibit Revenue.** Each year, ASN holds Renal Week, which—with nearly 14,000 participants and 850 speakers from the United States and abroad—is the world's largest annual meeting focused on kidney disease. A key aspect of Renal Week is the ASN Scientific Exposition. The exposition includes booths from approximately 180 commercial interests and not-for-profit organizations, such as the National Kidney Foundation.
2. **Educational Revenue.** In addition to Renal Week, ASN holds six to eight regional meetings (called Renal WeekEnds) each winter. The Society also convenes an Annual Board Review Course and Update and posts educational content on its website. Commercial interests provide unrestricted educational grants to help support these activities.
3. **Promotional Revenue.** Renal Week, Renal WeekEnds, and the Annual Board Review Course and Update also include opportunities for promotional support. Commercial interests help cover the costs of promotional items that are important to the success of a specific meeting. For example, ASN solicits external support to cover the cost of providing a wireless local area network in the convention center during Renal Week.
4. **Advertising Revenue.** ASN self-publishes the *Journal of the American Society of Nephrology* (JASN), the *Clinical Journal of the American Society of Nephrology* (CJASN), the *Nephrology Self-Assessment Program* (NephSAP), and *ASN Kidney News* (which was called *ASN Highlights* until this year). Commercial interests advertise in these publications as well as, on occasion, sponsor supplements to the journals and purchase reprints of articles.

Tab 2 provides ASN's "Corporate Support Opportunities" in 2009. This list outlines specific educational and promotional opportunities provided to commercial entities with interest in kidney disease.

From 2006 to the present, ASN did not solicit support from commercial interests for its research grants program. During this same period, ASN received no funding from foundations established by commercial interests, or from federal, state, or local government.

ASN Committee on Corporate Relations

ASN believes that it has a responsibility to assess—on a regular basis—potential conflicts of interest that relate to the execution of activities imperative to its mission. To this end, ASN in 2008 created a Committee on Corporate Relations chaired by John B. Stokes, MD, FASN, who is the Director of the Division of Nephrology at the University of Iowa Carver College of Medicine. Dr. Stokes and the committee conducted a comprehensive year-long assessment of ASN’s mechanisms for managing relationships with commercial interests.

Earlier this year, the committee presented its final report to the ASN Council, which is ASN’s governing body. The council unanimously approved the report; endorsed the committee’s 10 recommendations on how to design, monitor, and enforce regulations that improve ASN’s interactions with commercial interests; and developed a detailed strategy for implementing these recommendations.

As an important first step in this plan, ASN in August 2009 added a section to its website called, “ASN Conflict of Interest Initiative: Transparency in Relationships with Commercial Interests.” Located at <http://www.asn-online.org/coi/>, this part of ASN’s website—which is open to the public and not password protected—summarizes ASN action and policy, provides informational resources, and includes a feedback mechanism related to conflicts of interest. Besides serving as a communication vehicle with ASN members, other members of the renal community, and the public, this site is intended to serve as a mechanism for increasing transparency related to ASN’s relationship with commercial interests.

Additionally, ASN published the final report of the Committee on Corporate Relations in the September 2009 issue of JASN (**Tab 3**). The article, entitled “ASN Policy on Managing Conflicts of Interest,” is also posted on the section of the website dedicated to conflicts of interest. Besides summarizing the committee’s 10 recommendations for improving ASN’s interactions with commercial interests, the article includes a table that compares ASN’s approach to these issues to recent recommendations from the Association of American Medical Colleges, the Institute of Medicine, and “Professional Medical Associations and Their Relationships with Industry: A Proposal for Controlling Conflicts of Interest” (published earlier this year in the *Journal of the American Medical Association*).

In September 2009, ASN distributed “ASN Policy on Managing Conflicts of Interest” and a link to the conflict of interest section of its website to the executive directors of nearly 40 medical societies. ASN invited these leaders to “to engage in an exchange of ideas and resources regarding conflict of interest in a shared effort to improve policies and management of this issue.” Seeking “to stimulate and participate in the growing dialogue on conflicts of interest,” ASN welcomed comments regarding the article and information concerning each organization’s efforts to address potential conflicts.

During ASN Renal Week 2009—which took place October 27 to November 1 in San Diego, CA—Bernard Lo, MD, presented the Christopher R. Blagg Endowed Lectureship on “How to Identify and Manage Conflicts.” The Blagg Lecture is one of the most prominent, well-attended, and visible sessions at Renal Week. In addition to serving as Director of the Program in Medical Ethics at the University of California, San Francisco, School of Medicine, Dr. Lo chaired the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice.

Since January 2008, ASN has taken concrete steps to increase transparency related to the Society's relationship with commercial interests. These steps are aligned with recommendations from external organizations, such as the Institute of Medicine, and according to the rules of ACCME. Moreover, ASN commends the Council of Medical Specialty Societies (CMSS) for attempting to develop a "Code of Conduct for Specialty Societies in Relationships with Industry." ASN sincerely hopes that CMSS's efforts will result in consistent rules for all medical societies.

Specific Responses to the Five Questions

In your letter, you ask ASN to "explain [its] policies for accepting industry funding and the disclosure requirements for [its] top executives and board members" from January 1, 2006, to the present. To provide this explanation, you asked ASN to answer the following five questions.

Question 1: Please describe the policies for accepting industry funding and whether or not ASN allows companies to place restrictions or provide guidance on how funding will be spent.

ASN does not allow commercial interests to place restrictions, provide guidance, or dictate in any way how the Society will spend funding derived from commercial interests. As previously stated, ASN receives funding from commercial interests for one of four purposes: exhibits, educational activities, promotional items, and advertising. ASN has established mechanisms for creating "firewalls" between each activity and the sources of funding.

Since 2001, ASN has contracted with an association management company (SmithBucklin) to manage all aspects of the Scientific Exposition during Renal Week. As a result, SmithBucklin interacts directly with every entity, including commercial interests, interested in exhibiting during the meeting. This separation between ASN and SmithBucklin helps ensure that exhibitors have no influence over Renal Week.

As stated in the *Exhibitors Prospectus* for Renal Week, ASN also "supports the ethical codes of conduct on interactions with health care professionals including, but not limited to, Advanced Medical Technology Association (AdvaMed) "Code of Ethics on Interaction with Health Care Professionals"; the American Medical Association (AMA) "Gifts to Physicians from Industry Ethical Opinion 8.0611"; the Pharmaceutical Research and Manufacturers of America (PhRMA) "Code on Interactions with Healthcare Professionals"; and other ethical guidelines and standards that describe the appropriate relationships between physicians and industry. By articulating, publishing, and enforcing this policy, ASN sends as strong a statement as possible about the Society's expectations for the ethical behavior of exhibitors at Renal Week.

In terms of educational activities, ASN adheres to ACCME's six "Standards for Commercial Support." As an accredited provider of CME credits, ASN has met ACCME standards since 2000. The first standard, "Independence," requires ASN to "ensure" that commercial interests have no role in identifying "CME needs" for nephrologists, determining the "educational objectives" for activities, selecting and presenting "content," selecting "all persons and organizations" positioned "to control the content," selecting the "educational methods" for delivering this content, and evaluating the educational activity.

To meet this standard, ASN has separated planning, delivering, and evaluating educational content from fundraising. ASN members and staff involved in any aspect of the Society's educational activities—from identifying the educational needs of nephrologists to developing educational objectives for each activity to finalizing content to choosing speakers to selecting educational content to evaluating the activity—are not allowed to interact with commercial interests and vice versa.

“Resolution of Personal Conflicts of Interest” is the second ACCME standard. This standard requires ASN “to show that everyone who is in a position to control the content of an education activity has disclosed all relevant financial relationships with any commercial interest to the provider.” ACCME “defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months [of the educational activity] that create a conflict of interest.” ASN is also required to disqualify any “individual who refuses to disclose relevant financial relationships.” Finally, ACCME requires ASN to implement “a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners.”

ASN requires that all of the members of the oversight and planning committees for the Society's educational activities as well as all of the speakers (including moderators) must complete the “ASN Financial/Other Interests Disclosure Form” (**Tab 4**). ASN's conflict of interest policy requires:

- Disclosure “of any financial or other interest that might be construed as resulting in an actual, potential, or perceived conflict.”
- Disclosure of “any financial relationship held by” everyone who is in the position to control the content of an educational activity as well as his or her spouse or partner.
- Submission of the completed form “whether or not” an individual has a relationship requiring disclosure.

The ASN Program Committee or Postgraduate Education Committee reviews the completed forms, addresses any potential conflicts, and is prepared to disqualify anyone who refuses to disclose relevant financial relationships.

Third, ASN follows ACCME's standard concerning “Appropriate Use of Commercial Support.” This standard has 13 rules to which ASN must adhere:

1. ASN “must make all decisions regarding the disposition and disbursement of commercial support.”
2. ASN “cannot be required by a commercial interest to accept advice or services concerning teachers, authors, or participants or other education matters, including content, from a commercial interest as conditions of contributing funds or services.”
3. “All commercial support associated with a CME activity must be given with the full knowledge and approval of” ASN.
4. “The terms, conditions, and purposes of the commercial support must be documented in a written agreement between the commercial supporter that includes” ASN “and its educational partner(s). The agreement must include” ASN, “even if the support is given directly to” ASN's “educational partner or a joint sponsor.”
5. “The written agreement must specify the commercial interest that is the source of commercial support.”
6. “Both the commercial supporter and” ASN “must sign the written agreement between the commercial supporter and” ASN.

7. ASN “must have written policies and procedures governing honoraria and reimbursement of out-of-pocket expenses for planners, teachers, and authors.”
8. ASN, “the joint sponsor, or designated educational partner must pay directly any teacher or author honoraria or reimbursement of out-of-pocket expenses in compliance with” ASN’s “written policies and procedures.”
9. “No other payment shall be given to the director of the activity, planning committee members, teachers or authors, joint sponsor, or any others involved with the supported activity.”
10. “If teachers or authors are listed on the agenda as facilitating or conducting a presentation or session, but participate in the remainder of an educational event as a learner, their expenses can be reimbursed and honoraria can be paid for their teacher or author role only.”
11. “Social events or meals at CME activities cannot compete with or take precedence over the educational events.”
12. ASN “may not use commercial support to pay for travel, lodging, honoraria, or personal expenses for non-teacher or nonauthor participants of a CME activity.” ASN “may use commercial support to pay for travel, lodging, honoraria, or personal expenses for bona fide employees and volunteers of the provider, joint sponsor or educational partner.”
13. ASN “must be able to produce accurate documentation detailing the receipt and expenditure of the commercial support.”

For nearly one decade, ASN has taken steps to make these 13 rules more stringent. The Society decided in 2003 that only ASN could provide CME credits for the Society’s educational activities. As a result, ASN stopped allowing “educational partners,” such as medical education and communication companies (MECCs), to hold satellite symposia during Renal Week. In 2006, ASN then ceased jointly sponsoring educational activities with other entities. Finally, ASN in 2009 prohibited MECCs from submitting grant requests or securing funds for educational activities connected with the Society. At this time, therefore, ASN is responsible for every aspect of its educational activities.

The fourth standard is “Appropriate Management of Associated Commercial Promotion.” To meet this standard, ASN cannot allow “arrangements for commercial exhibits or advertisements” to “influence planning or interfere with the presentation, nor can they be a condition of the provision of commercial support for CME activities.” In addition, ACCME prohibits “product-promotion material or product-specific advertisement of any type...in or during CME activities.” ACCME adds, “The juxtaposition of editorial and advertising material on the same products or subjects must be avoided.” ASN must also keep all educational activities separate from “promotional activities.” According to this standard, “educational materials that are part of a CME activity, such as slides, abstracts and handouts, cannot contain any advertising, trade name or a product-group message.” And, finally, ASN “cannot use a commercial interest as the agent providing a CME activity to learners”; for example, ASN cannot distribute a self study for a CME activity through a commercial interest.

To meet this standard, ASN separates responsibility for educational activities from responsibility for the exhibit hall (which is managed by SmithBucklin) and from responsibility for promotional items. For example, the ASN Program Committee reviews abstracts that are submitted for presentation during Renal Week. An independent group of ASN members reviews the abstracts, which are blinded and scored. Any abstract that is identified as potentially containing bias (advertising, trade names, or product group messages) is flagged, withdrawn from the abstract pool, and subjected to a secondary review by the ASN Program Committee.

Either the ASN Program Committee or Postgraduate Education Committee is also responsible for reviewing slides and handouts for compliance and potential bias. This function is performed either by the appropriate committee member (based on professional expertise) or the moderator(s) of a specific session. If a potential noncompliance issue is identified, it is referred to the committee for resolution.

“Content and Format without Commercial Bias” is the fifth standard. To meet this standard, ASN must ensure that the “content or format of a CME activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.” In addition, presentations “must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. If the CME educational material or content includes trade names, where available trade names from several companies should be used, not just trade names from a single company.”

In addition to requiring full disclosure for everyone who can influence content, ASN instructs all speakers to provide balanced, scientifically rigorous, and evidence-based presentations. The moderators of each session are responsible for ensuring that treatment options are fairly discussed. All presentations are reviewed for conflicts of interest and, if identified, are resolved prior to the activity. All commercial support is disclosed to activity participants in printed meeting material, on a slide prior to the particular educational session, and on signage outside the meeting room.

Moderators—who are chosen by either the ASN Program Committee or Postgraduate Education Committee—monitor presentations, case discussions, and presenters’ answers to questions. These moderators ensure a balanced discussion of the material and are instructed to rectify verbally any perception of bias. Session moderators are also asked to act as “observers” of the session to specifically identify bias on the part of any speaker or participant. Each moderator is instructed to manage the bias, if appropriate, and to report via an electronic submission form, information on observed bias.

The sixth and final ACCME standard is “Disclosures Relevant to Potential Commercial Bias.” Before an educational activity begins, ASN must:

- Ensure that each individual involved in the educational activity (including those responsible for planning the activity as well as speakers) “disclose to learners any relevant financial relationship(s),” which includes the name of the individual, the name of the commercial interest(s), and the “nature of the relationship the person has with each commercial interest.”
- Report when an individual has “no relevant financial relationship(s).”
- Ensure that the “source of all support from commercial interests must be disclosed to learners.”
- Report when “commercial support is ‘in-kind,’” including “the nature of the support.”
- Ensure that “trade names or a product group message” is never included in the disclosure.

Anyone who influences content must complete the “ASN Financial/Other Interests Disclosure Form” before an educational activity. ASN uses this information to identify potential bias. For example, during the planning of Renal Week 2009, two abstracts were flagged by the reviewers as promoting one particular dialysis provider. The abstracts were coauthored by an employee of this company and portrayed the provider in a positive manner. These abstracts were referred back to the ASN Program Committee. The committee reviewed the abstracts and determined that even though they had been coauthored by an employee of a commercial interest and highlighted a single dialysis provider, the

abstracts were reporting results of clinical investigations that were commissioned by the Centers for Medicare and Medicaid Services (CMS), thereby highlighting their importance to the nephrology community.

ACCME's "Standards for Commercial Support" provide an excellent framework for ensuring that ASN's educational activities are free from influence by commercial interests. The ASN Council has also taken steps to strengthen the firewall between fundraising and planning, delivering, and evaluating educational content. These steps are a result of improvements in ASN's governance structure and changes among the Society's staff.

In 2007, ASN restructured its governance to create a series of oversight committees that report directly to the ASN Council. One of these panels, the ASN Education Committee, is now responsible for overseeing every educational activity, including Renal Week, Renal WeekEnds, the Annual Board Review Course, and educational content on the website. The committees, working groups, other panels, and individuals responsible for planning, delivering, and evaluating ASN's educational activities report directly to the ASN Education Committee. Before this change, ASN Director of Postgraduate Education Robert G. Narins, MD, FASN, was responsible for overseeing ASN's educational activities, working with various committees and individuals to plan these activities, and reporting directly to the council.

Additionally, Tod Ibrahim succeeded Karen L. Campbell, PhD, as ASN Executive Director in January 2008. During his first year, Mr. Ibrahim hired Phillip Kokemueller as ASN's first Chief Learning Officer and Kara Davis as ASN's first Senior Manager of Business Development. Mr. Kokemueller is responsible for ensuring the success of ASN's educational activities and maintaining ASN's compliance with ACCME. Ms. Davis is responsible for generating external support for ASN's educational activities and promotional items. Thus, ASN has further separated education from fundraising by establishing these two staff positions.

To generate external support for promotional items, ASN follows ACCME's fourth standard for commercial support: "Appropriate Management of Associated Commercial Promotion." As a result, ASN:

- Does not allow commercial exhibits or advertisements to influence planning or interfere with the presentation of educational material.
- Does not allow commercial exhibits to be a condition of the provision of commercial support for educational activities.
- Prohibits product-promotion material or product-specific advertisement of any type...in or during educational activities.
- Avoids the juxtaposition of editorial and advertising material on the same products or subjects.
- Conducts all educational activities separately from promotional activities.
- Requires educational material that is part of an educational activity (such as slides, abstracts, and handouts) cannot contain any advertising, trade name, or a product-group message.
- Does not use a commercial interest as the agent providing a educational activity to members.

The first three sources of revenue that ASN generates from commercial interests (exhibits, educational activities, and promotional items) are closely related to the Society's educational activities.

Advertising—the fourth and final source of revenue generated from commercial interests—is closely related to the Society's efforts as a publisher.

Since 2004, ASN has contracted with an advertising sales firm (Scherago International) to manage all aspects of advertising in the Society's four publications: JASN, CJASN, NephSAP, and Kidney News. As a result, Scherago International interacts directly with every entity, including commercial interests, interested in advertising in one of the journals. This separation between ASN and Scherago International helps ensure that exhibitors have no opportunity to influence the journals' content.

Each issue of the journals also includes the same statement, "The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety." Additionally, Scherago International's "rate cards" for the journals explain that the editor-in-chief of each journal has the right to reject an advertisement.

The editor-in-chief of each journal is also responsible for requesting, reviewing, and maintaining disclosure forms for the editorial staff of that publication. Each issue of an ASN journal states this fact: "To avoid conflicts of interest, all members of the editorial staff have completed financial disclosure forms which are available for review in appropriate circumstances when requested from the editor-in-chief."

Besides traditional advertisements, ASN allowed the editors-in-chief of JASN and CJASN to consider publishing supplements to the journals that are sponsored by commercial interests. (Neither NephSAP nor ASN *Kidney News* published supplements.) The editorial teams for JASN and CJASN are completely responsible for all of the content in a supplement. Since 2006, ASN has published 11 such supplements (five in JASN and six in CJASN).

Earlier this year, the ASN Publications Committee—which oversees the Society's journals—recommended that ASN after 2009 discontinue single-sponsored supplements and discourage multi-sponsor supplements unless these publications involve such entities as the National Institutes of Health or the Doris Duke Charitable Foundation.

In addition to advertising and supplements, the advertising category includes revenue from reprints. Since 2005, ASN has contracted with a commercial printer (Cadmus Professional Communications) to solicit, process, and distribute reprints of articles published in JASN and CJASN. (Neither NephSAP nor ASN *Kidney News* sell reprints.) Because Cadmus is responsible for handling all transactions related to reprints, a firewall exists between ASN and the reprint business.

Moreover, the editors of JASN and CJASN do not receive a report as to which articles are purchased as reprints or which external entities (including commercial interests, institutions, and authors) have purchased reprints. This policy further ensures that the editors have no incentive to publish an article specifically to generate sales from reprints.

Question 2: If ASN allows companies to place restrictions on industry funding, then please explain all restrictions and/or guidance for each transfer of value from industry. For every transfer of value with a restriction, please provide the following information: year of transfer, name of company, and restriction placed on funding.

As previously discussed, ASN does not allow commercial interests to place restrictions, provide guidance, or dictate in any way how the Society will spend revenue derived from commercial interests. As further evidence of this fact, **Tab 5** provides examples of ASN's agreements with commercial interests related to:

1. The Scientific Exposition.
2. Educational Activities.
3. Promotional Items.
4. Advertising.

These agreements clearly indicate that ASN is independent from commercial interests.

Question 3: Please explain what policies, if any, that ASN plans to adopt to ensure transparency of funding in order to provide a greater public trust in the independence of your organization.

Since January 1, 2008, ASN has:

- Hired a new Executive Director who was specifically charged with ensuring that ASN maintained educational and scientific objectivity as well as institutional integrity through disclosure, evaluation, standardization, and transparency in interactions with industry.
- Created a Committee on Corporate Relations to conduct a comprehensive year-long assessment of ASN's mechanisms for managing relationships with commercial interests.
- Approved unanimously the final report of this committee, which included 10 recommendations on how to design, monitor, and enforce regulations that improve ASN's interactions with commercial interests.
- Developed a detailed strategy for implementing these recommendations (that the Society is now executing).
- Published the final report of the Committee on Corporate Relations, entitled "ASN Policy on Managing Conflicts of Interest," in the September 2009 issue of JASN.
- Added a section on ASN's website ("ASN Conflict of Interest Initiative: Transparency in Relationships with Commercial Interests") to highlight ASN's activities in this arena.
- Distributed "ASN Policy on Managing Conflicts of Interest" and a link to the conflict of interest section of its website to the executive directors of nearly 40 medical societies; invited these leaders to "to engage in an exchange of ideas and resources regarding conflict of interest in a shared effort to improve policies and management of this issue."
- Invited Dr. Lo to present the Christopher R. Blagg Endowed Lectureship on "How to Identify and Manage Conflicts" during ASN Renal Week 2009.

The final report of the ASN Committee on Corporate Relations recommended highlighting the importance of separating education from fundraising, prohibiting any interaction with MECCs, renaming the "ASN Financial/Other Interests Disclosure Form," continuing to emphasize the importance of having abstract

reviews look for potential bias, trying to use “educated reviewers” to monitor every educational activity, clarifying the importance of session moderators, prohibiting individuals involved in corporate-sponsored exhibits from participating in educational activities (and vice versa), developing clear guidelines for informing ASN members and staff (and commercial interests) about the Society’s expectations and policies, and forming a committee to review ASN’s activities and policies related to conflicts of interest.

To date, ASN has implemented eight of the committee’s 10 recommendations. In 2010, ASN will implement the final two recommendations:

1. Form the Conflicts of Interest Management Committee to review the Society’s COI activities and policies as well as its instituted documentation processes.
2. Rename the present disclosure form as the “Financial Disclosure and Potential Conflict of Interest Form.”

In addition to forming the committee and renaming the form, ASN plans to expand the section of its website dedicated to conflicts of interest. For example, ASN distributes a “Faculty Disclosure Digest” at Renal Week. In 2010, ASN will post on the website the information summarized in the digest, which lists the financial disclosures for each of the nearly 850 faculty at Renal Week.

ASN also looks forward to continuing its efforts to work with the leaders of other medical societies to improve policies and management of conflicts of interest. Along these lines, ASN hopes to contribute to CMSS’s efforts to develop a “Code of Conduct for Specialty Societies in Relationships with Industry.”

Question 4: Please explain your policies on disclosure of outside income by your top executives and board members.

ASN is governed by an eight-member council that includes the Society’s President, President-Elect, Past President, and Secretary-Treasurer as well as four councilors. No member of the staff, including the executive director, has a vote in council discussions.

Each year, ASN requires all of its volunteers, including the eight councilors, to complete disclosure forms. These forms solicit information about both financial relationships with commercial entities and leadership activities in other organizations. ASN expects everyone who completes a disclosure form to update this form during the course of the year. Before every meeting of the council or any other ASN-sponsored panel, participants are asked to update their disclosures.

ASN has never had an Executive Director who is a physician. At the council’s request when he was hired, the current executive director, Mr. Ibrahim, agreed not to serve on the leadership of any commercial interest (such as on the board of directors of a pharmaceutical company). In addition, Mr. Ibrahim agreed not to accept any payment from entities related to ASN (or its mission), including commercial interests. In turn, Mr. Ibrahim has instructed the rest of the staff (none of whom is a physician) to follow these policies as well.

Question 5: Please provide the disclosures of outside income filed with your organization by your top executives and board members.

Tab 6 provides the disclosures of outside income filed by the eight members of the ASN Council. Because none of the staff is allowed to receive payment from entities related to ASN (or its mission), including commercial interests, the staff, including Mr. Ibrahim, have nothing to disclose.


In 2010, the new ASN Conflicts of Interest Management Committee will review the disclosures from the ASN Council. The committee is also responsible for identifying any potential conflicts of interest, and, if needed, working with the individual leader and the council to implement a plan for managing these conflicts.

Furthermore, each of the eight members of the ASN Council is a fulltime employee of a US university or medical school. Therefore, the councilors are also required to file disclosures with these institutions, which review the information, identify potential conflicts of interest, and, if needed, work with individual councilors to implement a plan to manage these conflicts. This institutional review provides an additional layer of scrutiny for each member of the ASN Council.

Again, thank you for the opportunity to describe ASN's relationship with commercial interests since January 1, 2006. ASN is pleased to respond to your request and meet your deadline for providing this information. Given this short timeline, ASN recognizes that you or your staff may ask ASN to provide additional information or to clarify any aspect of its response or information reflected on the timeline (**Tab 7**).

To discuss this letter, the background material, or ASN, please contact Mr. Ibrahim at (202) 416-0666 or tibrahim@asn-online.org.

Sincerely,



Sharon Anderson, MD, FASN
President



Tod Ibrahim
Executive Director

Enclosure

<u>Company</u>	<u>Exhibit Revenue</u>	<u>Educational Revenue</u>	<u>Promotional Revenue</u>	<u>Advertising Revenue</u>	<u>Total Revenue</u>
Abbott	\$ 140,400.00	\$ 660,000.00	\$ 125,000.00	\$ 171,768.00	\$ 1,097,168.00
Academy for Healthcare Education				\$ 4,300.00	\$ 4,300.00
Adis International				\$ 11,407.00	\$ 11,407.00
Advanced Renal Technologies	\$ 3,100.00				\$ 3,100.00
Alcavis International, Inc.	\$ 6,200.00				\$ 6,200.00
Altus Pharmaceuticals Inc.	\$ 6,200.00				\$ 6,200.00
American Regent, Inc.	\$ 35,100.00			\$ 35,534.00	\$ 70,634.00
American Renal Associates, Inc. (ARA)	\$ 6,200.00			\$ 33,609.00	\$ 39,809.00
Amgen	\$ 132,600.00	\$ 735,000.00	\$ 483,000.00	\$ 192,913.00	\$ 1,543,513.00
AngioDynamics, Inc.	\$ 15,600.00			\$ 104,217.00	\$ 119,817.00
Apheresis Technologies, Inc.	\$ 3,100.00				\$ 3,100.00
Arbor Research Collaborative for Health	\$ 3,100.00				\$ 3,100.00
Arrow International	\$ 6,200.00				\$ 6,200.00
Asahi Kasei Medical	\$ 23,400.00				\$ 23,400.00
Aspreva Pharmaceuticals Corp.		\$ 135,871.00			\$ 135,871.00
Astellas Pharma US, Inc.	\$ 65,500.00	\$ 275,000.00	\$ 60,000.00	\$ 4,521.00	\$ 405,021.00
AstraZeneca			\$ 10,000.00	\$ 2,342.00	\$ 12,342.00
AtCor Medical, Inc.	\$ 6,200.00				\$ 6,200.00
Athena Diagnostics, Inc.	\$ 3,100.00			\$ 4,870.00	\$ 7,970.00
B. Braun Medical Inc.	\$ 23,400.00				\$ 23,400.00
Bard Access Systems	\$ 6,200.00				\$ 6,200.00
Baxter Healthcare	\$ 97,500.00			\$ 23,532.00	\$ 121,032.00
Bayer Healthcare Diagnostic Division	\$ 3,100.00			\$ 14,394.00	\$ 17,494.00
Biosite Incorporated	\$ 6,200.00	\$ -	\$ 10,000.00	\$ 3,223.00	\$ 19,423.00
Blackwell Publishing, Inc.	\$ 3,100.00				\$ 3,100.00
Boehringer-Ingelheim		\$ 180,000.00			\$ 180,000.00
Bostwick Laboratories	\$ 3,100.00				\$ 3,100.00
Braintree Laboratories				\$ 59,617.00	\$ 59,617.00
Brandywine Medical Management Services, Inc.	\$ 6,200.00				\$ 6,200.00
Bristol-Myers Squibb	\$ 6,200.00		\$ 10,000.00	\$ 6,015.00	\$ 22,215.00
Bristol-Myers Squibb/Sanofi-Aventis	\$ 23,400.00				\$ 23,400.00
Calwest Homes, LLC	\$ 3,100.00				\$ 3,100.00
CardioMed Supplies Inc.	\$ 3,100.00				\$ 3,100.00
CGB Enterprises	\$ 3,100.00				\$ 3,100.00
Charles River Laboratories	\$ 3,100.00				\$ 3,100.00
CHF Solutions, Inc.	\$ 3,100.00			\$ 7,611.00	\$ 10,711.00
Clarus Health			\$ 9,000.00		\$ 9,000.00
Clinical Computing, Inc.	\$ 6,200.00				\$ 6,200.00
Cook Medical	\$ 3,100.00				\$ 3,100.00
CORA Corp.	\$ 3,100.00				\$ 3,100.00
Coromega Company, The	\$ 3,100.00				\$ 3,100.00
CourierMed Inc.	\$ 3,100.00				\$ 3,100.00
Cybernius Medical	\$ 3,100.00				\$ 3,100.00
Dade Behring	\$ 3,100.00				\$ 3,100.00
Daiichi Sankyo, Inc.	\$ 15,600.00				\$ 15,600.00
DaVita	\$ 15,600.00				\$ 15,600.00
Daxor Corporation	\$ 3,100.00				\$ 3,100.00
Dialysis Corporation of America (DCA)	\$ 6,200.00				\$ 6,200.00
Dialysis Solutions Inc.	\$ 3,100.00				\$ 3,100.00
Diasol Inc.	\$ 3,100.00				\$ 3,100.00
DocTalk	\$ 3,100.00				\$ 3,100.00
Dustri-Verlag	\$ 3,100.00				\$ 3,100.00
DVA Laboratory Services	\$ 3,100.00				\$ 3,100.00
Eli Lilly and Company			\$ 10,000.00		\$ 10,000.00
Elsevier				\$ 2,100.00	\$ 2,100.00
Encyclopaedia Britannica Products	\$ 3,100.00				\$ 3,100.00
European Renal Association (EDTA)	\$ 3,100.00				\$ 3,100.00
Excelsior Medical	\$ 3,100.00				\$ 3,100.00
Exemplo Medical, LLC	\$ 3,100.00				\$ 3,100.00
F. Hoffman - La Roche				\$ 10,875.00	\$ 10,875.00
Fleming and Company	\$ 3,100.00				\$ 3,100.00
Fresenius Medical Care	\$ 136,500.00			\$ 17,221.00	\$ 153,721.00
Fujisawa				\$ 9,844.00	\$ 9,844.00
GAMBRO	\$ 78,000.00				\$ 78,000.00
GE Healthcare	\$ 3,100.00	\$ 135,000.00			\$ 138,100.00
Genzyme	\$ 140,400.00	\$ 422,000.00	\$ 131,000.00	\$ 91,127.00	\$ 784,527.00
GIA Medical	\$ 3,100.00				\$ 3,100.00
Gore & Associates	\$ 3,100.00				\$ 3,100.00
GS Worldwide				\$ 17,300.00	\$ 17,300.00
GTI Diagnostics	\$ 3,100.00				\$ 3,100.00
Hancock Jaffe Laboratories, Inc.	\$ 3,100.00				\$ 3,100.00
Health Informatics, Inc. (HII)	\$ 6,200.00				\$ 6,200.00
HemoCue, Inc.	\$ 3,100.00				\$ 3,100.00
Hoffman La Roche			\$ 100,000.00		\$ 100,000.00
HRA Research	\$ 3,100.00				\$ 3,100.00
Hygeia Marketing Associates, Inc.	\$ 3,100.00				\$ 3,100.00
ICU Medical, Inc.	\$ 15,600.00				\$ 15,600.00

Immunodiagnostic Systems Inc (IDS Inc)	\$	3,100.00			\$	3,100.00
Immutopics International	\$	3,100.00			\$	3,100.00
Institute for Continuing Healthcare Education	\$	3,100.00			\$	3,100.00
International Society of Nephrology	\$	3,850.00			\$	3,850.00
JMS North America Corp.	\$	6,200.00			\$	6,200.00
Karger Publishers	\$	6,200.00			\$	6,200.00
Kemp Goldberg Strategic Comm				\$	4,300.00	\$ 4,300.00
Keryx Biopharmaceuticals, Inc.	\$	15,600.00				\$ 15,600.00
Kibow Biotech Inc.	\$	3,100.00				\$ 3,100.00
Kidney Center Inc. (KCI)	\$	3,100.00				\$ 3,100.00
King Pharmaceuticals, Inc.			\$	195,000.00		\$ 195,000.00
Kuraray Medical Inc					\$	2,736.00
LeMaitre Vascular, Inc.	\$	3,100.00				\$ 3,100.00
Liberty Dialysis, LLC	\$	3,100.00				\$ 3,100.00
Lippincott Williams & Wilkins	\$	3,100.00				\$ 3,100.00
Luitpold Pharm				\$	13,835.00	\$ 13,835.00
Mar Cor Purification (MCP)	\$	3,100.00				\$ 3,100.00
MarCap Corporation	\$	3,100.00				\$ 3,100.00
MCM Environmental Technologies, Inc.	\$	3,100.00				\$ 3,100.00
MedBuild	\$	3,100.00				\$ 3,100.00
medCOMP	\$	15,600.00				\$ 15,600.00
Med-Conduit, Inc.	\$	3,100.00				\$ 3,100.00
MediBuild Development Group, LLC	\$	3,100.00				\$ 3,100.00
MEDIGROUP, INC.	\$	3,100.00				\$ 3,100.00
MediHoney				\$	1,608.00	\$ 1,608.00
Medionics International Inc.	\$	3,100.00				\$ 3,100.00
Medisystems Corporation	\$	15,600.00				\$ 15,600.00
Medscape from WebMD/eMedicine from WebMD	\$	15,600.00				\$ 15,600.00
Merck & Co. Inc.			\$	36,800.00	\$	7,335.00
MIQS Software	\$	3,100.00				\$ 3,100.00
Mission Pharmacal Company	\$	3,100.00				\$ 3,100.00
Molded Products, Inc.	\$	3,100.00				\$ 3,100.00
Nabi Biopharmaceuticals	\$	62,400.00	\$	200,000.00	\$	32,975.00
National Renal Alliance	\$	6,200.00				\$ 6,200.00
Nationwide Laboratory Services	\$	3,100.00				\$ 3,100.00
Nature Publishing Group	\$	3,100.00				\$ 3,100.00
Nephrology News & Issues (NN&I)	\$	3,100.00				\$ 3,100.00
NephroPath	\$	6,200.00				\$ 6,200.00
Nephros, Inc.	\$	6,200.00				\$ 6,200.00
Nephro-Tech, Inc.	\$	3,100.00				\$ 3,100.00
New England Journal of Medicine, The	\$	3,100.00			\$	4,600.00
Next Generation Clinical Research	\$	3,100.00				\$ 3,100.00
NIKKISO CO., LTD.	\$	15,600.00				\$ 15,600.00
Nipro Medical Corporation	\$	23,400.00				\$ 23,400.00
Novaflux Technologies, Inc.	\$	3,100.00				\$ 3,100.00
Novartis Pharmaceuticals Corporation	\$	3,100.00			\$	60,636.00
NovoSci Corp	\$	3,100.00				\$ 3,100.00
NxStage Medical, Inc.	\$	6,200.00	\$	-	\$	5,000.00
Ortho Biotech Products L.P.	\$	81,100.00	\$	202,000.00		\$ 283,100.00
PeaceHealth	\$	3,100.00				\$ 3,100.00
Pentec Health	\$	6,200.00			\$	2,473.00
Pfizer Inc.	\$	46,800.00				\$ 46,800.00
Photon Technology International, Inc.	\$	3,100.00				\$ 3,100.00
QOL Medical	\$	3,100.00				\$ 3,100.00
Quantitative Medical Systems (QMS)	\$	3,100.00				\$ 3,100.00
Reed Business Information					\$	3,804.00
Reliant Pharmaceuticals					\$	25,859.00
Renal & Urology News	\$	3,100.00				\$ 3,100.00
Renal Business Today	\$	3,100.00				\$ 3,100.00
Renal CarePartners, Inc.	\$	3,100.00				\$ 3,100.00
Renal Research Institute					\$	2,800.00
Renal Solutions, Inc.	\$	6,200.00				\$ 6,200.00
Renal Ventures Management, LLC	\$	6,200.00				\$ 6,200.00
RenalTrax	\$	3,100.00				\$ 3,100.00
Renesan Software	\$	3,100.00				\$ 3,100.00
Research Diets, Inc.	\$	3,100.00				\$ 3,100.00
RMS Lifeline Inc.	\$	6,200.00				\$ 6,200.00
Roche	\$	78,000.00	\$	616,000.00	\$	20,000.00
Rockwell Medical Technologies, Inc.	\$	3,100.00				\$ 3,100.00
Ross Products Division Abbott Laboratories	\$	3,100.00				\$ 3,100.00
Sanofi Aventis					\$	15,974.00
Satellite Laboratory Services, LLC	\$	6,200.00				\$ 6,200.00
Saunders - Mosby/Elsevier	\$	3,100.00				\$ 3,100.00
Scantibodies Clinical Laboratory	\$	3,100.00			\$	15,986.00
Schwarz Pharma					\$	8,852.00
Shire Pharmaceuticals	\$	163,800.00	\$	973,362.00	\$	177,300.00
Sigma-Tau Pharmaceuticals, Inc.	\$	15,600.00				\$ 15,600.00
Soaptronic, LLC	\$	3,100.00				\$ 3,100.00

ASN in 2006

Spire Biomedical, Inc.	\$	6,200.00			\$	11,665.00	\$	17,865.00
Springer	\$	3,100.00					\$	3,100.00
Synergy Dialysis Associates	\$	3,100.00					\$	3,100.00
Terumo Interventional Systems	\$	3,100.00					\$	3,100.00
The Binding Site Inc.	\$	6,200.00			\$	4,300.00	\$	10,500.00
THERAKOS, Inc.	\$	3,100.00					\$	3,100.00
Toray Medical Co., Ltd.	\$	3,100.00					\$	3,100.00
TrakAnemia	\$	3,100.00					\$	3,100.00
Transonic Systems Inc.	\$	7,100.00			\$	3,091.00	\$	10,191.00
Tyco Healthcare/Kendall	\$	3,100.00					\$	3,100.00
Vasc-Alert	\$	3,100.00					\$	3,100.00
Vascular Access Centers	\$	3,100.00					\$	3,100.00
ViraCor Laboratories	\$	3,100.00					\$	3,100.00
Visonex, LLC	\$	3,100.00					\$	3,100.00
Watson Nephrology	\$	46,800.00	\$	457,000.00	\$	81,000.00	\$	211,491.00
Wedgewood Communications							\$	11,200.00
Wiley	\$	3,100.00					\$	3,100.00
WS Far IR Medical Technology Co., Ltd.	\$	3,100.00					\$	3,100.00
Wyeth Pharmaceuticals	\$	62,400.00	\$	215,000.00	\$	115,000.00	\$	125,435.00
Total	\$	2,071,150.00	\$	5,401,233.00	\$	1,383,100.00	\$	1,785,237.00
							\$	10,640,720.00

<u>Company</u>	<u>Exhibit Revenue</u>	<u>Educational Revenue</u>	<u>Promotional Revenue</u>	<u>Advertising Revenue</u>	<u>Total Revenue</u>
Abbott	\$ 155,600.00	\$ 710,000.00	\$ 125,000.00	\$ 166,001.00	\$ 1,156,601.00
Advanced Renal Technologies	\$ 3,200.00				\$ 3,200.00
AKDHC	\$ 3,200.00				\$ 3,200.00
Alcavis International, Inc.	\$ 6,400.00				\$ 6,400.00
AMAG Pharmaceuticals, Inc.	\$ 15,600.00				\$ 15,600.00
American Regent, Inc.	\$ 35,100.00			\$ 43,973.00	\$ 79,073.00
American Renal Associates, Inc. (ARA)	\$ 6,400.00			\$ 49,537.00	\$ 55,937.00
American Vascular Access	\$ 3,200.00				\$ 3,200.00
Amgen	\$ 132,600.00	\$ 988,000.00	\$ 483,000.00	\$ 200,691.00	\$ 1,804,291.00
AngioDynamics, Inc.	\$ 15,600.00				\$ 15,600.00
Angiotech	\$ 6,400.00				\$ 6,400.00
Antibodyshop A/S	\$ 3,200.00				\$ 3,200.00
Apheresis Technologies, Inc.	\$ 3,200.00				\$ 3,200.00
Arbor Research Collaborative for Health	\$ 3,200.00				\$ 3,200.00
Arrow International	\$ 6,400.00				\$ 6,400.00
Asahi Kasei Medical America	\$ 23,400.00				\$ 23,400.00
Astellas Pharma US, Inc.	\$ 65,600.00	\$ 170,000.00		\$ 123,023.00	\$ 358,623.00
AtCor Medical, Inc. (USA)	\$ 6,400.00				\$ 6,400.00
Athena Diagnostics, Inc.	\$ 3,200.00			\$ 2,571.00	\$ 5,771.00
Athenian Science Bookstore				\$ 2,101.00	\$ 2,101.00
B. Braun Medical Inc.	\$ 23,400.00				\$ 23,400.00
Bard Access Systems	\$ 6,400.00			\$ 2,707.00	\$ 9,107.00
Baxter Healthcare	\$ 97,500.00			\$ 61,040.00	\$ 158,540.00
Bayer Healthcare Pharmaceuticals	\$ 6,400.00	\$ 145,000.00		\$ 2,707.00	\$ 154,107.00
BioPhysics Assay Laboratory, Inc.	\$ 3,200.00				\$ 3,200.00
Biosite Incorporated	\$ 3,200.00			\$ 2,707.00	\$ 5,907.00
Blackwell Publishing, Inc.	\$ 3,200.00				\$ 3,200.00
Boehringer Ingelheim		\$ 170,000.00		\$ 2,938.00	\$ 172,938.00
Bracco				\$ 32,373.00	\$ 32,373.00
Braintree Labs				\$ 10,099.00	\$ 10,099.00
Breckenridge Pharmaceutical, Inc.	\$ 3,200.00				\$ 3,200.00
Bristol-Myers Squibb			\$ 10,000.00		\$ 10,000.00
CardioMed Supplies Inc.	\$ 3,200.00				\$ 3,200.00
Charles River Laboratories	\$ 3,200.00				\$ 3,200.00
Clarion Health				\$ 2,707.00	\$ 2,707.00
Clinical Computing, Inc.	\$ 6,400.00				\$ 6,400.00
CORA Corp.	\$ 3,100.00				\$ 3,100.00
CourierMed Inc.	\$ 3,200.00			\$ 18,197.00	\$ 21,397.00
CreatiVasc Medical	\$ 3,200.00				\$ 3,200.00
Cubist Pharmaceuticals	\$ 15,600.00	\$ 170,000.00	\$ 20,000.00	\$ 48,871.00	\$ 254,471.00
CVRx, Inc.	\$ 3,200.00			\$ 4,500.00	\$ 7,700.00
Cybernius Medical	\$ 3,200.00				\$ 3,200.00
Dade Behring	\$ 3,200.00			\$ 5,869.00	\$ 9,069.00
Daiichi Sankyo, Inc.	\$ 15,600.00				\$ 15,600.00
DaVita	\$ 15,600.00			\$ 14,566.00	\$ 30,166.00
Daxor Corporation	\$ 3,200.00				\$ 3,200.00
DCA	\$ 6,400.00				\$ 6,400.00
DiagnOptics Technologies B.V.	\$ 3,200.00				\$ 3,200.00
Dialysis & Transplantation	\$ 3,200.00				\$ 3,200.00
Dialysis at Sea Cruises	\$ 3,100.00				\$ 3,100.00
Dialysis Solutions Inc.	\$ 3,200.00				\$ 3,200.00
Diasol Inc.	\$ 3,100.00				\$ 3,100.00
Dustri-Verlag Dr. Karl Feistle GmbH & Co. KG	\$ 3,200.00				\$ 3,200.00
DVA Laboratory Services	\$ 3,100.00				\$ 3,100.00
ENACT - Education Network for Anemia in Chronic	\$ 3,200.00				\$ 3,200.00
European Renal Association (EDTA)	\$ 3,100.00				\$ 3,100.00
Excelsior Medical	\$ 3,100.00				\$ 3,100.00
Exemplo Medical, LLC	\$ 3,200.00				\$ 3,200.00
F. Hoffman - La Roche				\$ 44,305.00	\$ 44,305.00
Faculty of 1000 Medicine	\$ 3,200.00				\$ 3,200.00
FMQAI: The Florida ESRD Network	\$ 3,200.00				\$ 3,200.00
Forest Research Institute		\$ 135,725.00			\$ 135,725.00
Foundation Medical Staffing	\$ 3,200.00				\$ 3,200.00
Fresenius Medical Care	\$ 117,000.00	\$ 170,000.00		\$ 44,904.00	\$ 331,904.00
GAMBRO	\$ 78,000.00			\$ 3,330.00	\$ 81,330.00
Gambro BCT	\$ 3,100.00			\$ 6,831.00	\$ 9,931.00
GE Healthcare	\$ 3,200.00				\$ 3,200.00
Genentech, Inc.	\$ 3,200.00	\$ 221,000.00			\$ 224,200.00
Genzyme	\$ 140,400.00	\$ 503,000.00	\$ 146,000.00	\$ 206,515.00	\$ 995,915.00
GIA Medical	\$ 3,200.00				\$ 3,200.00
GlaxoSmithKline				\$ 6,095.00	\$ 6,095.00
HDC Medical, Inc.	\$ 3,200.00				\$ 3,200.00
Health Informatics, Inc. (HII)	\$ 6,400.00				\$ 6,400.00

HemoCue, Inc.	\$	3,200.00			\$	3,200.00			
HRA Research	\$	3,200.00			\$	3,200.00			
Huffman Developments	\$	3,200.00			\$	3,200.00			
I3CME				\$	4,800.00	\$	4,800.00		
ICU Medical, Inc.	\$	15,600.00		\$	4,500.00	\$	20,100.00		
iMedica	\$	3,200.00				\$	3,200.00		
Immutopics International	\$	3,200.00				\$	3,200.00		
INEOS			\$	25,000.00		\$	25,000.00		
International Society of Nephrology	\$	3,200.00				\$	3,200.00		
JMS North America Corp.	\$	6,400.00				\$	6,400.00		
JSM Healthcare Inc.	\$	6,400.00				\$	6,400.00		
Karger Publishers	\$	6,400.00				\$	6,400.00		
Keryx Biopharmaceuticals, Inc.	\$	15,600.00		\$	2,995.00	\$	18,595.00		
Kibow Biotech Inc.	\$	3,200.00				\$	3,200.00		
Kidney Center Inc. (KCI)	\$	6,400.00				\$	6,400.00		
Lahoy				\$	1,200.00	\$	1,200.00		
Liberty Dialysis, LLC	\$	3,200.00				\$	3,200.00		
Lippincott Williams & Wilkins	\$	3,200.00				\$	3,200.00		
Mar Cor Purification (MCP)	\$	3,200.00				\$	3,200.00		
MedActionPlan.Com LLC	\$	3,200.00				\$	3,200.00		
MedBuild, a division of Modular Space	\$	3,200.00				\$	3,200.00		
medCOMP	\$	15,600.00				\$	15,600.00		
MediBuild Development Group	\$	3,200.00				\$	3,200.00		
MEDIGROUP, INC.	\$	3,200.00				\$	3,200.00		
Medionics International Inc.	\$	3,200.00				\$	3,200.00		
Medisystems Corporation	\$	6,400.00				\$	6,400.00		
Medivisor	\$	3,100.00				\$	3,100.00		
Merck & Co. Inc.			\$	50,000.00	\$	4,081.00	\$	54,081.00	
MIQS Software	\$	3,200.00				\$	3,200.00		
Mission Pharmacal Company	\$	3,100.00				\$	3,100.00		
Mosby/Saunders-Elsevier	\$	3,200.00				\$	3,200.00		
Mundicongres, SL					\$	2,384.00	\$	2,384.00	
Nabi Pharmaceuticals			\$	212,000.00			\$	212,000.00	
National Renal Alliance	\$	6,400.00				\$	6,400.00		
Nationwide Laboratory Services	\$	6,400.00				\$	6,400.00		
Nature Publishing Group	\$	3,200.00				\$	3,200.00		
Nephrocor	\$	15,600.00			\$	8,100.00	\$	23,700.00	
Nephrology News & Issues (NN&I)	\$	3,200.00				\$	3,200.00		
NephroPath	\$	6,400.00			\$	8,500.00	\$	14,900.00	
Nephros, Inc.	\$	6,400.00				\$	6,400.00		
Nephro-Tech, Inc.	\$	3,200.00				\$	3,200.00		
New England Journal of Medicine, The	\$	3,200.00			\$	4,500.00	\$	7,700.00	
Next Generation Clinical Research	\$	3,200.00				\$	3,200.00		
NIKKISO CO., LTD.	\$	15,600.00				\$	15,600.00		
Nipro Medical Corporation	\$	15,600.00				\$	15,600.00		
Nova Biomedical	\$	3,200.00				\$	3,200.00		
Novaflux Technologies, Inc.	\$	3,200.00				\$	3,200.00		
Novartis Pharmaceuticals Corporation	\$	6,400.00			\$	84,264.00	\$	90,664.00	
Novo Nordisk, Inc.			\$	220,000.00	\$	10,769.00	\$	230,769.00	
NovoSci Corp	\$	3,200.00				\$	3,200.00		
NutrePletion Resources	\$	3,200.00				\$	3,200.00		
NxStage Medical, Inc.	\$	6,400.00				\$	6,400.00		
Ortho Biotech Products , Inc.	\$	81,100.00	\$	196,000.00		\$	27,529.00	\$	304,629.00
Otsuka America Pharmaceutical, Inc.			\$	144,000.00			\$	144,000.00	
Oxford University Press	\$	3,200.00				\$	3,200.00		
Pentec Health	\$	3,200.00				\$	3,200.00		
Pfizer Inc.	\$	23,400.00			\$	24,205.00	\$	47,605.00	
PhosLo	\$	62,400.00				\$	62,400.00		
Physicians Choice Dialysis	\$	3,200.00				\$	3,200.00		
PLC Medical Systems, Inc.	\$	3,200.00			\$	1,200.00	\$	4,400.00	
Porter Novelli			\$	25,000.00			\$	25,000.00	
Prime Medica					\$	9,000.00	\$	9,000.00	
Probetex, Inc.	\$	3,200.00				\$	3,200.00		
Quantitative Medical Systems (QMS)	\$	3,100.00				\$	3,100.00		
Redsense Medical AB	\$	6,400.00				\$	6,400.00		
Reliant Pharmaceuticals					\$	41,259.00	\$	41,259.00	
Renal & Urology News	\$	3,100.00				\$	3,100.00		
Renal Business Today/Virgo Publishing	\$	3,100.00				\$	3,100.00		
Renal CarePartners, Inc.	\$	6,400.00				\$	6,400.00		
Renal Solutions, Inc.	\$	6,400.00				\$	6,400.00		
Renal Ventures Management, LLC	\$	6,400.00				\$	6,400.00		
RenaLab, Inc.	\$	3,200.00				\$	3,200.00		
Renesan Software	\$	3,200.00				\$	3,200.00		
Research Diets, Inc.	\$	3,200.00				\$	3,200.00		

RMS Lifeline Inc.	\$	6,400.00				\$	6,400.00			
Roche	\$	159,900.00	\$	505,000.00	\$	142,400.00	\$	137,374.00	\$	944,674.00
Rockwell Medical Technologies, Inc.	\$	3,200.00					\$	3,200.00		
Ross Products Division Abbott Laboratories	\$	3,200.00					\$	3,200.00		
Sanofi-Aventis						\$	5,223.00	\$	5,223.00	
Satellite Healthcare, Inc.	\$	6,400.00					\$	6,400.00		
Satellite Laboratory Services, LLC	\$	15,600.00					\$	15,600.00		
Saunders/Mosby-Elsevier	\$	3,200.00					\$	3,200.00		
Savient Pharmaceuticals	\$	6,400.00	\$	145,000.00			\$	151,400.00		
Scantibodies Clinical Laboratory	\$	3,200.00				\$	15,988.00	\$	19,188.00	
Scius						\$	4,800.00	\$	4,800.00	
Servier						\$	2,905.00	\$	2,905.00	
Shire Pharmaceuticals	\$	163,800.00	\$	475,000.00	\$	85,000.00	\$	144,718.00	\$	868,518.00
Sigma-Tau Pharmaceuticals, Inc.	\$	15,600.00	\$	170,000.00				\$	185,600.00	
Spire Biomedical, Inc.	\$	6,400.00						\$	6,400.00	
Springer	\$	3,200.00						\$	3,200.00	
Sudler and Hennessey						\$	7,500.00	\$	7,500.00	
The Binding Site Inc.	\$	6,400.00				\$	41,800.00	\$	48,200.00	
The Fortus Group	\$	3,200.00						\$	3,200.00	
Therakos						\$	2,243.00	\$	2,243.00	
Toray Medical Co., Ltd.	\$	15,600.00						\$	15,600.00	
Total Renal Care						\$	10,500.00	\$	10,500.00	
Transonic Systems Inc.	\$	3,200.00						\$	3,200.00	
Tyco Healthcare/Kendall	\$	3,200.00						\$	3,200.00	
UpToDate	\$	3,200.00						\$	3,200.00	
US Renal Care, Inc.	\$	6,400.00						\$	6,400.00	
Vasc-Alert	\$	3,200.00						\$	3,200.00	
Vascular Access Centers	\$	3,200.00						\$	3,200.00	
ViraCor Laboratories	\$	3,200.00						\$	3,200.00	
Visonex	\$	3,200.00						\$	3,200.00	
VisualSonics Inc.	\$	3,200.00						\$	3,200.00	
VitalRemedyMD	\$	3,200.00						\$	3,200.00	
Watson Pharmaceutical	\$	46,800.00	\$	442,000.00	\$	105,000.00	\$	178,536.00	\$	772,336.00
Wedgewood Communications						\$	11,600.00	\$	11,600.00	
Williams Scotsman	\$	3,100.00				\$	2,707.00	\$	5,807.00	
WS Far IR Medical Technology Co., Ltd.	\$	3,200.00						\$	3,200.00	
Wyeth Pharmaceuticals	\$	62,400.00				\$	117,007.00	\$	179,407.00	
Total	\$	2,187,900.00	\$	5,891,725.00	\$	1,216,400.00	\$	2,031,345.00	\$	11,327,370.00

<u>Company</u>	<u>Exhibit Revenue</u>	<u>Educational Revenue</u>	<u>Promotional Revenue</u>	<u>Advertising Revenue</u>	<u>Total Revenue</u>
aaXess Health, LLC	\$ 3,200.00				\$ 3,200.00
Abbott	\$ 103,800.00	\$ 680,000.00	\$ 100,000.00	\$ 168,924.00	\$ 1,052,724.00
Advanced Renal Technologies	\$ 3,200.00				\$ 3,200.00
Alcavis HDC	\$ 6,400.00				\$ 6,400.00
AMAG Pharmaceuticals, Inc.	\$ 78,000.00	\$ 290,000.00	\$ 75,000.00	\$ 112,695.00	\$ 555,695.00
American Access Care	\$ 3,200.00				\$ 3,200.00
American Regent, Inc.	\$ 35,100.00			\$ 74,723.00	\$ 109,823.00
American Renal Associates, Inc.	\$ 6,400.00			\$ 3,698.00	\$ 10,098.00
American Vascular Access	\$ 3,200.00				\$ 3,200.00
Amgen	\$ 132,600.00	\$ 689,000.00	\$ 189,000.00	\$ 203,112.00	\$ 1,213,712.00
AngioDynamics, Inc.	\$ 6,400.00				\$ 6,400.00
Angiotech Interventional	\$ 6,400.00				\$ 6,400.00
Aperio	\$ 6,400.00				\$ 6,400.00
Apheresis Technologies, Inc.	\$ 3,100.00				\$ 3,100.00
Arbor Research Collaborative for Health	\$ 3,200.00				\$ 3,200.00
Arrow, A Teleflex Medical Co.	\$ 6,400.00				\$ 6,400.00
Asahi Kasei Medical America	\$ 9,600.00				\$ 9,600.00
Astellas Pharma US, Inc.	\$ 68,800.00	\$ 135,000.00		\$ 110,922.00	\$ 314,722.00
AtCor Medical, Inc. (USA)	\$ 6,400.00				\$ 6,400.00
Athena Diagnostics, Inc.	\$ 3,200.00			\$ 34,761.00	\$ 37,961.00
B. Braun Medical Inc.	\$ 23,400.00			\$ 4,045.00	\$ 27,445.00
Bain Medical Equipment	\$ 3,200.00				\$ 3,200.00
Banff Allograft Pathology Meeting 2009	\$ 3,100.00				\$ 3,100.00
Bard Access Systems	\$ 15,600.00				\$ 15,600.00
Baxter Healthcare	\$ 97,500.00			\$ 1,090.00	\$ 98,590.00
Bayer Healthcare Pharmaceuticals	\$ 9,600.00				\$ 9,600.00
BioPhysics Assay Laboratory, Inc.	\$ 3,200.00				\$ 3,200.00
BioPorto Diagnostics A/S	\$ 3,200.00			\$ 2,295.00	\$ 5,495.00
Biosite Diagnostics				\$ 2,843.00	\$ 2,843.00
Boehringer-Ingelheim Pharmaceuticals, Inc.	\$ 23,400.00		\$ 20,000.00		\$ 43,400.00
Brandywine Medical Management Services, Inc.	\$ 3,200.00				\$ 3,200.00
Braintree Laboratories				\$ 20,192.00	\$ 20,192.00
Bristol-Myers Squibb	\$ 6,400.00	\$ 376,005.00	\$ 22,000.00	\$ 10,186.00	\$ 414,591.00
CardioMed Supplies Inc.	\$ 3,200.00				\$ 3,200.00
CaridianBCT	\$ 3,100.00			\$ 3,500.00	\$ 6,600.00
Clarion Health				\$ 8,529.00	\$ 8,529.00
Clinical Computing, Inc.	\$ 3,200.00				\$ 3,200.00
Communication Interface Co LTD			\$ 50,000.00		\$ 50,000.00
Compas, Inc				\$ 45,814.00	\$ 45,814.00
CompHealth	\$ 3,200.00				\$ 3,200.00
Content Ed Net Communications				\$ 11,417.00	\$ 11,417.00
Covidien	\$ 3,200.00		\$ 5,000.00		\$ 8,200.00
CreatiVasc Medical	\$ 3,200.00				\$ 3,200.00
Cubist Pharmaceuticals	\$ 15,600.00			\$ 34,991.00	\$ 50,591.00
CVRx, Inc.	\$ 3,100.00				\$ 3,100.00
Cybernius Medical	\$ 3,200.00				\$ 3,200.00
Daiichi Sankyo, Inc.	\$ 15,600.00				\$ 15,600.00
DaVita	\$ 15,600.00		\$ 15,000.00	\$ 4,500.00	\$ 35,100.00
Daxor Corporation	\$ 3,200.00				\$ 3,200.00
DCA	\$ 6,400.00				\$ 6,400.00
DCRX Infusion	\$ 3,200.00				\$ 3,200.00
Dermaport	\$ 3,200.00				\$ 3,200.00
DiagnOptics	\$ 3,200.00				\$ 3,200.00
Dialysis & Transplantation	\$ 3,200.00				\$ 3,200.00
Dialysis at Sea Cruises	\$ 3,100.00				\$ 3,100.00
Dialysis Recruiting Specialists/The Fortus Group	\$ 3,200.00				\$ 3,200.00
Dustri-Verlag	\$ 3,200.00				\$ 3,200.00
Elsevier Brazil				\$ 6,007.00	\$ 6,007.00
ENACT - Education Network for Anemia in Chronic	\$ 3,200.00				\$ 3,200.00
Exemplo Medical, LLC	\$ 3,200.00				\$ 3,200.00
F. Hoffman - La Roche				\$ 94,978.00	\$ 94,978.00
Falcon Medica LLC			\$ 2,000.00		\$ 2,000.00
Fresenius Medical Care - North America	\$ 202,800.00	\$ 410,000.00	\$ 100,000.00	\$ 91,298.00	\$ 804,098.00
G.I.A. Medical	\$ 3,200.00				\$ 3,200.00
GAMBRO	\$ 93,600.00			\$ 9,034.00	\$ 102,634.00
GE Healthcare	\$ 6,400.00				\$ 6,400.00
Genentech		\$ 179,226.00			\$ 179,226.00
Genzyme	\$ 140,400.00	\$ 378,000.00	\$ 141,849.00	\$ 158,149.00	\$ 818,398.00
Gilead Sciences				\$ 11,373.00	\$ 11,373.00
Hart Press				\$ 4,649.00	\$ 4,649.00
Health Informatics International	\$ 6,400.00				\$ 6,400.00
Hema Metrics	\$ 3,200.00				\$ 3,200.00
HemoCue, Inc.	\$ 3,200.00				\$ 3,200.00
HRA Research	\$ 3,100.00				\$ 3,100.00
Huffman Developments	\$ 3,200.00				\$ 3,200.00

ICU Medical, Inc.	\$	15,600.00			\$	15,600.00
Immutopics International	\$	3,200.00			\$	3,200.00
Innovations For Dialysis	\$	3,100.00			\$	3,100.00
Integrated Nephrology Network	\$	3,100.00			\$	3,100.00
Inverness Medical / Biosite	\$	3,200.00			\$	3,200.00
Johnson and Johnson			\$	15,000.00	\$	2,167.00
JMS North America Corp.	\$	6,400.00			\$	6,400.00
Karger Publishers	\$	6,400.00			\$	6,400.00
Kibow Biotech Inc.	\$	6,400.00			\$	3,825.00
Kidney Center Inc. (KCI)	\$	6,400.00			\$	6,400.00
Kidney Community Emergency Response Coalition	\$	3,100.00			\$	3,100.00
Liberty Dialysis, LLC	\$	15,600.00			\$	15,600.00
Lifeline Vascular Access	\$	6,400.00			\$	6,400.00
Lippincott Williams & Wilkins	\$	3,200.00			\$	3,200.00
Mar Cor Purification (MCP)	\$	3,200.00			\$	3,200.00
Marriott Vacation Club	\$	3,200.00			\$	3,200.00
MedBuild	\$	3,200.00			\$	3,200.00
medCOMP	\$	15,600.00			\$	15,600.00
MediBuild Development Group	\$	3,200.00			\$	3,200.00
MEDIGROUP, INC.	\$	3,200.00			\$	3,200.00
Medionics International Inc.	\$	3,200.00			\$	3,200.00
Merck & Co., Inc.			\$	50,000.00	\$	5,220.00
Meso Scale Discovery	\$	3,200.00			\$	3,200.00
MIQS Software	\$	3,200.00			\$	3,200.00
Mosby / Saunders - Elsevier	\$	3,200.00			\$	3,200.00
National Kidney and Urologic Diseases	\$	3,100.00			\$	3,100.00
Nationwide Laboratory Services	\$	3,100.00			\$	3,100.00
Nature Publishing Group	\$	3,200.00			\$	3,200.00
Nephrocor	\$	3,200.00			\$	6,608.00
Nephrology News & Issues (NN&I)	\$	3,200.00			\$	3,200.00
NephroPath	\$	6,400.00			\$	24,500.00
Nephros, Inc.	\$	3,200.00			\$	3,200.00
Nephro-Tech, Inc.	\$	3,200.00			\$	3,200.00
New England Journal of Medicine, The	\$	3,200.00			\$	3,200.00
NIKKISO CO., LTD.	\$	15,600.00			\$	15,600.00
Nipro Medical Corporation	\$	23,400.00			\$	23,400.00
Nova Biomedical	\$	3,100.00			\$	3,100.00
Novartis Pharmaceuticals Corporation	\$	19,200.00	\$	179,000.00	\$	55,000.00
Novo Nordisk Pharmaceuticals					\$	117,423.00
NutrePletion Resources	\$	3,200.00			\$	16,697.00
NxStage Medical, Inc.	\$	15,600.00			\$	3,200.00
Ortho Biotech Products LP	\$	81,200.00	\$	15,000.00	\$	30,600.00
Otsuka America Pharmaceutical, Inc.	\$	15,600.00	\$	196,000.00	\$	128,691.00
Oxford University Press	\$	3,200.00	\$	145,000.00	\$	405,891.00
Pentec Health	\$	3,100.00			\$	270,800.00
Pfizer Inc.	\$	23,400.00			\$	3,200.00
Physicians Choice Dialysis	\$	3,200.00			\$	4,976.00
Practice One	\$	3,200.00			\$	8,076.00
ProPath	\$	3,200.00			\$	28,049.00
Quality Dialysis	\$	3,200.00			\$	3,200.00
Quantitative Medical Systems	\$	3,100.00			\$	3,200.00
Quest Information Services					\$	3,100.00
Redsense Medical AB	\$	6,400.00			\$	4,643.00
Renal & Urology News	\$	3,100.00			\$	6,400.00
Renal Business Today/Virgo Publishing	\$	3,100.00			\$	3,100.00
Renal CarePartners, Inc.	\$	6,400.00			\$	6,400.00
Renal Solutions, Inc.	\$	3,200.00			\$	3,200.00
Renal Ventures Management, LLC	\$	6,400.00			\$	6,400.00
RenaLab	\$	3,200.00			\$	3,200.00
Reprints Desk					\$	14,504.00
Reprints Unlimited					\$	2,960.00
Research Diets, Inc.	\$	3,200.00			\$	3,200.00
Roche	\$	62,400.00	\$	20,000.00	\$	73,336.00
Rockwell Medical Technologies, Inc.	\$	6,400.00			\$	155,736.00
Satellite Healthcare/Wellbound	\$	6,400.00			\$	6,400.00
Satellite Laboratory Services, LLC	\$	15,600.00			\$	6,400.00
Savient Pharmaceuticals			\$	10,000.00	\$	15,600.00
Saunders / Mosby - Elsevier	\$	3,100.00			\$	13,112.00
Scantibodies Clinical Laboratory	\$	6,400.00			\$	3,100.00
Servier					\$	20,403.00
Shire Pharmaceuticals	\$	163,800.00	\$	55,000.00	\$	3,338.00
Siemens Healthcare Diagnostics	\$	3,200.00			\$	315,680.00
Sigma-Tau Pharmaceuticals, Inc.	\$	6,400.00			\$	3,200.00
Spectra Laboratories	\$	15,600.00			\$	6,400.00
Spire Biomedical, Inc.	\$	6,400.00			\$	17,076.00
Springer	\$	3,100.00			\$	6,400.00
					\$	3,100.00

ASN in 2008

Sysmex America, Inc.	\$	3,100.00				\$	3,100.00
Takeda					\$	7,589.00	\$ 7,589.00
TauroPharm GmbH	\$	3,200.00					\$ 3,200.00
The Binding Site Inc.	\$	6,400.00			\$	45,019.00	\$ 51,419.00
The British Library					\$	8,090.00	\$ 8,090.00
Ther-Rx Corporation	\$	3,200.00					\$ 3,200.00
Toray Medical Co., Ltd.	\$	6,400.00					\$ 6,400.00
Total Quality Medical	\$	3,100.00					\$ 3,100.00
Tran PA-C Inc	\$	3,200.00					\$ 3,200.00
Transonic Systems Inc.	\$	3,200.00					\$ 3,200.00
Ultroid Technologies, Inc.	\$	3,200.00					\$ 3,200.00
University of Iowa Diagnostic Laboratories	\$	3,200.00					\$ 3,200.00
UpToDate	\$	3,200.00					\$ 3,200.00
USACO					\$	2,399.00	\$ 2,399.00
US Renal Care, Inc.	\$	6,400.00					\$ 6,400.00
Vasc-Alert	\$	3,200.00					\$ 3,200.00
Vascular Access Centers	\$	3,200.00					\$ 3,200.00
Veeda Clinical Research	\$	3,100.00					\$ 3,100.00
Visonex	\$	3,200.00					\$ 3,200.00
VisualSonics Inc.	\$	3,200.00					\$ 3,200.00
VitalRemedyMD	\$	3,200.00					\$ 3,200.00
Voxmedia International					\$	15,257.00	\$ 15,257.00
Wall Bed Systems	\$	3,200.00					\$ 3,200.00
Watson Pharmaceutical	\$	58,500.00	\$	425,000.00	\$	95,000.00	\$ 77,519.00 \$ 656,019.00
Wiley Blackwell	\$	3,200.00					\$ 3,200.00
Williams Scotsman	\$	3,100.00					\$ 3,100.00
WoltersKluwer Health Pharma					\$	17,245.00	\$ 17,245.00
Wyeth Pharmaceuticals	\$	15,600.00			\$	83,565.00	\$ 99,165.00
Z Protein Laboratories, Inc.	\$	3,200.00					\$ 3,200.00
Total	\$	2,131,100.00	\$	4,082,231.00	\$	1,145,049.00	\$ 2,019,416.00 \$ 9,377,796.00

<u>Company</u>	<u>Exhibit Revenue</u>	<u>Educational Revenue</u>	<u>Promotional Revenue</u>	<u>Advertising Revenue</u>	<u>Total Revenue</u>
5strong Healthcare				\$ 1,960.00	\$ 1,960.00
Abbott Renal Care	\$ 42,800.00	\$ 441,819.00	\$ 115,000.00	\$ 155,747.00	\$ 755,366.00
Advanced Renal Technologies	\$ 3,400.00			\$ 1,366.00	\$ 4,766.00
Affymax, Inc.			\$ 55,000.00		\$ 55,000.00
Alcavis HDC	\$ 6,400.00				\$ 6,400.00
Alexion Pharmaceuticals	\$ 16,000.00			\$ 13,425.00	\$ 29,425.00
AMAG Pharmaceuticals, Inc.	\$ 96,000.00	\$ 291,819.00	\$ 175,000.00	\$ 361,950.00	\$ 924,769.00
American Access Care	\$ 3,400.00				\$ 3,400.00
American Regent, Inc.	\$ 36,000.00			\$ 37,153.00	\$ 73,153.00
American Renal Associates, Inc.	\$ 6,800.00				\$ 6,800.00
Amgen	\$ 220,000.00	\$ 454,638.00	\$ 230,000.00	\$ 126,061.00	\$ 1,030,699.00
AngioDynamics, Inc.	\$ 3,400.00			\$ 87,518.00	\$ 90,918.00
Angiotech Interventional	\$ 6,800.00				\$ 6,800.00
Aperio	\$ 6,800.00				\$ 6,800.00
Apheresis Technologies, Inc.	\$ 3,200.00				\$ 3,200.00
Arbor Research				\$ 4,378.00	\$ 4,378.00
Argutus Medical Limited	\$ 3,200.00				\$ 3,200.00
Asahi Kasei Medical America	\$ 10,200.00				\$ 10,200.00
Astellas Pharma US, Inc.	\$ 64,000.00	\$ 137,819.00			\$ 201,819.00
AstraZeneca		\$ 78,985.00			\$ 78,985.00
AtCor Medical, Inc. (USA)	\$ 6,800.00				\$ 6,800.00
Athena Diagnostics, Inc.	\$ 6,400.00			\$ 16,074.00	\$ 22,474.00
AWAK Technologies	\$ 3,400.00				\$ 3,400.00
B. Braun Medical Inc.	\$ 24,000.00		\$ 10,000.00	\$ 6,608.00	\$ 40,608.00
Bain Medical Equipment	\$ 24,000.00				\$ 24,000.00
Bard Access Systems	\$ 16,000.00				\$ 16,000.00
Baxter Healthcare Corporation	\$ 112,000.00		\$ 10,000.00	\$ 10,354.00	\$ 132,354.00
Biocommunications Development				\$ 17,969.00	\$ 17,969.00
BioPorto Diagnostics A/S	\$ 3,400.00			\$ 4,165.00	\$ 7,565.00
Biosite	\$ 3,400.00				\$ 3,400.00
Biosound Esaote	\$ 6,400.00				\$ 6,400.00
Bracco Diagnostics Inc.	\$ 6,800.00			\$ 24,800.00	\$ 31,600.00
Brandywine Medical Management Services, Inc.	\$ 3,400.00				\$ 3,400.00
Bristol-Myers Squibb	\$ 16,000.00	\$ 260,704.00		\$ 74,008.00	\$ 350,712.00
Boehringer-Ingelheim			\$ 15,000.00		\$ 15,000.00
CardioMed Supplies Inc.	\$ 3,400.00				\$ 3,400.00
CardianBCT	\$ 3,400.00			\$ 3,952.00	\$ 7,352.00
Centocor Ortho Biotech Products LP	\$ 64,000.00			\$ 19,466.00	\$ 83,466.00
Christopher Kidd & Associates, LLC	\$ 3,400.00				\$ 3,400.00
CMIC Co., Ltd.	\$ 3,400.00				\$ 3,400.00
CM&D Pharma Limited				\$ 3,112.00	\$ 3,112.00
Compas				\$ 123,445.00	\$ 123,445.00
Conectics				\$ 5,012.00	\$ 5,012.00
Covidien	\$ 3,400.00		\$ 5,000.00		\$ 8,400.00
Daiichi Sankyo, Inc.	\$ 10,200.00		\$ 40,000.00		\$ 50,200.00
DaVita	\$ 64,000.00				\$ 64,000.00
DCA	\$ 6,800.00			\$ 15,810.00	\$ 22,610.00
DiagnOptics	\$ 3,400.00				\$ 3,400.00
Dial Medical Supply				\$ 1,462.00	\$ 1,462.00
Dialysis & Transplantation	\$ 3,200.00				\$ 3,200.00
Diasol Inc./Discount Medical Supply Inc.	\$ 3,400.00				\$ 3,400.00
Diaverum	\$ 3,400.00				\$ 3,400.00
DoctorsXL	\$ 3,400.00				\$ 3,400.00
Dustri-Verlag	\$ 3,400.00				\$ 3,400.00
Elsevier Canada				\$ 3,844.00	\$ 3,844.00
EMD Healthcare Communications				\$ 9,458.00	\$ 9,458.00
ERA - EDTA	\$ 6,800.00				\$ 6,800.00
Evidence Meda SRL				\$ 3,561.00	\$ 3,561.00
Excerpta Medical Content Svcs				\$ 7,932.00	\$ 7,932.00
Exemplo Medical, LLC	\$ 6,800.00				\$ 6,800.00
R. Hoffmann-La Roche AG				\$ 4,708.00	\$ 4,708.00
Fairway Physicians Insurance Co., RRG	\$ 3,400.00				\$ 3,400.00
FibroGen				\$ 4,623.00	\$ 4,623.00
Forest Pharmaceuticals, Inc.	\$ 3,400.00				\$ 3,400.00
Fortus Group / Dialysis Recruiting Specialists	\$ 3,400.00				\$ 3,400.00
Fresenius Medical Care - North America	\$ 203,200.00	\$ 201,819.00	\$ 10,000.00	\$ 213,433.00	\$ 628,452.00
G.I.A. Medical	\$ 3,400.00				\$ 3,400.00
Gaia Healthcare Systems	\$ 3,200.00				\$ 3,200.00
GAMBRO	\$ 48,000.00			\$ 44,275.00	\$ 92,275.00
Genentech	\$ 64,000.00		\$ 20,000.00		\$ 84,000.00
Genzyme	\$ 64,000.00	\$ 235,819.00	\$ 150,800.00	\$ 189,909.00	\$ 640,528.00
Health Informatics International	\$ 6,800.00				\$ 6,800.00
Healthcare Media Europe Ltd				\$ 3,258.00	\$ 3,258.00
Hema Metrics	\$ 3,200.00				\$ 3,200.00
HRA Research	\$ 3,400.00				\$ 3,400.00
IKARIA	\$ 16,000.00	\$ 91,819.00	\$ 30,000.00		\$ 137,819.00
Immutopics International	\$ 3,400.00				\$ 3,400.00

Ineos Healthcare			\$	20,000.00		\$	20,000.00	
INN	\$	3,200.00				\$	3,200.00	
Inverness				\$	10,710.00	\$	10,710.00	
JMS North America Corporation	\$	6,800.00				\$	6,800.00	
Karger Publishers	\$	6,800.00				\$	6,800.00	
Kibow Biotech Inc.	\$	6,800.00		\$	3,527.00	\$	10,327.00	
Liberty Dialysis, LLC	\$	16,000.00				\$	16,000.00	
Licosa SPA				\$	13,181.00	\$	13,181.00	
Lippincott Williams & Wilkins	\$	3,400.00				\$	3,400.00	
LithoLink				\$	3,280.00	\$	3,280.00	
Mar Cor Purification (MCP)	\$	3,400.00				\$	3,400.00	
medCOMP	\$	6,800.00				\$	6,800.00	
Medelita	\$	3,200.00				\$	3,200.00	
Medical Education Institute, Inc.	\$	750.00				\$	750.00	
Medical Management & Data Services	\$	3,400.00				\$	3,400.00	
MEDIGROUP, INC.	\$	3,400.00				\$	3,400.00	
Medionics International Inc.	\$	3,400.00				\$	3,400.00	
Merck & Co., Inc.			\$	75,000.00		\$	75,000.00	
Meso Scale Discovery	\$	3,400.00				\$	3,400.00	
Mespere Lifesciences	\$	3,200.00				\$	3,200.00	
MIQS Software	\$	3,200.00				\$	3,200.00	
Nationwide Laboratory Services	\$	6,800.00				\$	6,800.00	
Nature Publishing Group	\$	3,400.00				\$	3,400.00	
Nephrian	\$	3,200.00				\$	3,200.00	
Nephroceuticals	\$	16,000.00				\$	16,000.00	
Nephrology News & Issues	\$	3,400.00				\$	3,400.00	
NephroPath	\$	6,800.00		\$	25,007.00	\$	31,807.00	
Nephros, Inc.	\$	3,400.00				\$	3,400.00	
Nephro-Tech, Inc.	\$	3,200.00				\$	3,200.00	
Next Generation Clinical Research	\$	3,400.00				\$	3,400.00	
NIKKISO CO., LTD.	\$	16,000.00				\$	16,000.00	
Nipro Medical Corporation	\$	24,000.00				\$	24,000.00	
Nova Biomedical	\$	3,200.00				\$	3,200.00	
Novartis Pharmaceuticals Corporation	\$	23,800.00		\$	35,000.00	\$	256,783.00	
Novo Nordisk, Inc.			\$	190,000.00		\$	190,000.00	
NutrePletion Resources	\$	3,200.00				\$	3,200.00	
NxStage Medical, Inc.	\$	10,200.00				\$	10,200.00	
One Source Reprints, Inc.					\$	2,944.00	\$	2,944.00
Otsuka America Pharmaceutical, Inc.	\$	16,000.00	\$	176,819.00	\$	25,000.00	\$	48,258.00
Oxford University Press	\$	3,200.00				\$	3,200.00	
Path Logic	\$	3,400.00			\$	2,082.00	\$	5,482.00
Pfizer Inc.	\$	24,000.00				\$	24,000.00	
Physicians Choice Dialysis	\$	3,200.00				\$	3,200.00	
PracticeOne	\$	3,200.00				\$	3,200.00	
Prente Publishing					\$	4,000.00	\$	4,000.00
Prime Clinical Systems, Inc.	\$	3,400.00				\$	3,400.00	
ProPath	\$	3,400.00				\$	3,400.00	
Quality Dialysis	\$	3,400.00				\$	3,400.00	
Questcor			\$	20,000.00		\$	20,000.00	
Quest Information Services (A-Z)					\$	2,209.00	\$	2,209.00
Renal & Urology News	\$	3,200.00				\$	3,200.00	
Renal Business Today/Virgo Publishing Medical Group	\$	3,200.00				\$	3,200.00	
Renal CarePartners, Inc.	\$	6,800.00			\$	2,762.00	\$	9,562.00
Renal Solutions, Inc.	\$	6,800.00				\$	6,800.00	
Renal Ventures Management, LLC	\$	6,800.00				\$	6,800.00	
RenaLab	\$	3,400.00				\$	3,400.00	
Reprint Publications GmbH					\$	2,399.00	\$	2,399.00
Reprints Unlimited					\$	5,386.00	\$	5,386.00
Research Diets, Inc.	\$	3,400.00				\$	3,400.00	
Roche			\$	5,000.00	\$	157,026.00	\$	162,026.00
Rockwell Medical Technologies, Inc.	\$	16,000.00				\$	16,000.00	
Sanofi Aventis					\$	41,980.00	\$	41,980.00
Satellite Healthcare/Wellbound	\$	6,800.00				\$	6,800.00	
Satellite Laboratory Services, LLC	\$	16,000.00				\$	16,000.00	
Saunders / Mosby - Elsevier	\$	6,800.00				\$	6,800.00	
Savient					\$	11,458.00	\$	11,458.00
Scantibodies Clinical Laboratory	\$	6,800.00			\$	5,967.00	\$	12,767.00
Sem Data Information Co Ltd					\$	4,895.00	\$	4,895.00
Servier					\$	8,349.00	\$	8,349.00
Shire Pharmaceuticals	\$	168,000.00			\$	182,694.00	\$	350,694.00
Siemens Healthcare Diagnostics	\$	3,400.00				\$	3,400.00	
Sigma-Tau Pharmaceuticals, Inc.	\$	6,800.00				\$	6,800.00	
Spectra Laboratories	\$	16,000.00				\$	16,000.00	
Springer Healthcare					\$	12,387.00	\$	12,387.00
Sysmex America, Inc.	\$	3,200.00				\$	3,200.00	
Takeda Pharmaceuticals North America	\$	36,000.00	\$	65,000.00	\$	18,287.00	\$	119,287.00
Teleflex Medical	\$	3,400.00				\$	3,400.00	
The Binding Site Inc.	\$	6,800.00			\$	58,786.00	\$	65,586.00

The Hart Press					\$	2,261.00	\$	2,261.00
the Jikei Univ Sch of Med Tokyo					\$	3,077.00	\$	3,077.00
Tissue Gnostics USA	\$	3,400.00					\$	3,400.00
Toray Medical Co., Ltd.	\$	3,400.00					\$	3,400.00
Transonic Systems Inc.	\$	3,400.00					\$	3,400.00
UpToDate	\$	3,200.00					\$	3,200.00
US Renal Care, Inc.	\$	6,800.00					\$	6,800.00
Vasc-Alert	\$	3,400.00					\$	3,400.00
Vascular Access Centers	\$	3,400.00					\$	3,400.00
Visonex	\$	6,800.00					\$	6,800.00
VisualSonics Inc.	\$	3,200.00					\$	3,200.00
VitalRemedyMD, Inc.	\$	3,200.00					\$	3,200.00
VM Verlagsservice					\$	4,478.00	\$	4,478.00
Watson Pharma	\$	60,000.00	\$	180,000.00	\$	20,000.00	\$	74,709.00
Wiley Blackwell	\$	3,400.00					\$	3,400.00
WoltersKluwer Health							\$	56,816.00
WS Far IR Medical Technology Co., Ltd.	\$	3,400.00					\$	3,400.00
Wyeth							\$	3,312.00
Z-Medica Corporation	\$	24,000.00					\$	24,000.00
Total	\$	2,115,950.00	\$	2,837,060.00	\$	1,035,800.00	\$	2,627,846.00
							\$	8,618,616.00